Novo Nordisk A/S (NVO) — closed signal from April 8, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on July 7, 2026.
Predicted vs. what happened
NVO price · publication thesis → realized outcomesplit-adjusted
$36.50 – $37.80Entry zone — fair-value band
$37.76Published — price the day we called it
$41.15Target — the price the thesis aimed for
$50.90Peak — highest point inside the window, not a realized return
$49.64Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 8 days.
Peak price
$50.90
peak on July 2, 2026 — not a realized returnPeak gain
+34.8%
peak, from the publication priceWindow close
$49.64
end-of-window price, context onlyDays to target
8
Window
April 8, 2026 – July 7, 2026
The thesis — published April 8, 2026
Predicted growth
+9%
over the measurement windowTarget price
$41.15
the price the thesis aimed forEntry zone
$36.50 – $37.80
the fair-value band we waited forPrice at publication
$37.76
published April 8, 2026Confidence
64%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Novo Nordisk is cheaper than many defensive drug companies and helps diversify a portfolio, but recent gains feel fragile. A lower-priced Wegovy HD could make the medicine easier to get and improve sentiment, yet it also increases pressure on profits while sales are slowing. The recent bounce looks extended and forecasts are still being lowered, so the setup is not strong.
Primary drivers
- High profits and lower price swings give defensive appeal
- Stock trades at a cheaper level versus similar healthcare names
- Lower-priced Wegovy HD can increase access but squeeze margins
- Recent recovery looks fragile while sales forecasts are being cut
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.